203 related articles for article (PubMed ID: 12604695)
21. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits.
Volz TJ; Hanson GR; Fleckenstein AE
J Neurochem; 2007 May; 101(4):883-8. PubMed ID: 17250674
[TBL] [Abstract][Full Text] [Related]
22. Methylphenidate-induced alterations in synaptic vesicle trafficking and activity.
Volz TJ; Farnsworth SJ; Hanson GR; Fleckenstein AE
Ann N Y Acad Sci; 2008 Oct; 1139():285-90. PubMed ID: 18991873
[TBL] [Abstract][Full Text] [Related]
23. Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles.
Volz TJ; Farnsworth SJ; Hanson GR; Fleckenstein AE
J Neurosci Methods; 2009 Feb; 177(1):177-82. PubMed ID: 18992277
[TBL] [Abstract][Full Text] [Related]
24. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors.
Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2008 Oct; 327(1):161-7. PubMed ID: 18591219
[TBL] [Abstract][Full Text] [Related]
25. Differences in reserpine-induced striatal dopamine output and content between female and male mice: implications for sex differences in vesicular monoamine transporter 2 function.
Dluzen DE; Bhatt S; McDermott JL
Neuroscience; 2008 Jul; 154(4):1488-96. PubMed ID: 18515015
[TBL] [Abstract][Full Text] [Related]
26. Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine.
Vaccari A; Saba PL; Ruiu S; Collu M; Devoto P
Toxicol Appl Pharmacol; 1996 Jul; 139(1):102-8. PubMed ID: 8685891
[TBL] [Abstract][Full Text] [Related]
27. Melatonin attenuates the amphetamine-induced decrease in vesicular monoamine transporter-2 expression in postnatal rat striatum.
Mukda S; Vimolratana O; Govitrapong P
Neurosci Lett; 2011 Jan; 488(2):154-7. PubMed ID: 21078367
[TBL] [Abstract][Full Text] [Related]
28. Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake.
Rau KS; Birdsall E; Volz TJ; Riordan JA; Baucum AJ; Adair BP; Bitter R; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2006 Aug; 318(2):676-82. PubMed ID: 16687477
[TBL] [Abstract][Full Text] [Related]
29. Effects of tetrabenazine on methamphetamine-induced hyperactivity in mice are dependent on order and time-course of administration.
Kuribara H
Pharmacol Biochem Behav; 1997 Jan; 56(1):9-14. PubMed ID: 8981603
[TBL] [Abstract][Full Text] [Related]
30. Relation between methamphetamine-induced monoamine depletions in the striatum and sequential motor learning.
Daberkow DP; Kesner RP; Keefe KA
Pharmacol Biochem Behav; 2005 May; 81(1):198-204. PubMed ID: 15894079
[TBL] [Abstract][Full Text] [Related]
31. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.
Chu PW; Hadlock GC; Vieira-Brock P; Stout K; Hanson GR; Fleckenstein AE
J Neurochem; 2010 Oct; 115(2):325-32. PubMed ID: 20649837
[TBL] [Abstract][Full Text] [Related]
32. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
Hansen JP; Riddle EL; Sandoval V; Brown JM; Gibb JW; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2002 Mar; 300(3):1093-100. PubMed ID: 11861820
[TBL] [Abstract][Full Text] [Related]
33. Methamphetamine exposure during the preweanling period causes prolonged changes in dorsal striatal protein kinase A activity, dopamine D2-like binding sites, and dopamine content.
Crawford CA; Williams MT; Newman ER; McDougall SA; Vorhees CV
Synapse; 2003 Jun; 48(3):131-7. PubMed ID: 12645038
[TBL] [Abstract][Full Text] [Related]
34. Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.
Wilhelm CJ; Johnson RA; Lysko PG; Eshleman AJ; Janowsky A
J Pharmacol Exp Ther; 2004 Sep; 310(3):1142-51. PubMed ID: 15102929
[TBL] [Abstract][Full Text] [Related]
35. Neuronal dopamine transporter activity, density and methamphetamine inhibition are differentially altered in the nucleus accumbens and striatum with no changes in glycosylation in rats behaviorally sensitized to methamphetamine.
Bjorklund NL; Sorg BA; Schenk JO
Synapse; 2008 Oct; 62(10):736-45. PubMed ID: 18651643
[TBL] [Abstract][Full Text] [Related]
36. Chronic stress augments the long-term and acute effects of methamphetamine.
Matuszewich L; Yamamoto BK
Neuroscience; 2004; 124(3):637-46. PubMed ID: 14980734
[TBL] [Abstract][Full Text] [Related]
37. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
[TBL] [Abstract][Full Text] [Related]
38. An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicity.
Fricks-Gleason AN; German CL; Hoonakker AJ; Friend DM; Ganesh KK; Carver AS; Hanson GR; Fleckenstein AE; Keefe KA
Synapse; 2016 Apr; 70(4):139-46. PubMed ID: 26799527
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibition of cyclooxygenase-2 exacerbates methamphetamine-induced dopamine depletion in the striatum in rats.
Zhang X; Dong F; Mayer GE; Bruch DC; Ren J; Culver B
Neuroscience; 2007 Dec; 150(4):950-8. PubMed ID: 17988800
[TBL] [Abstract][Full Text] [Related]
40. Persistence of tolerance to methamphetamine-induced monoamine deficits.
Danaceau JP; Deering CE; Day JE; Smeal SJ; Johnson-Davis KL; Fleckenstein AE; Wilkins DG
Eur J Pharmacol; 2007 Mar; 559(1):46-54. PubMed ID: 17239369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
